Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11)
Conditions
Interventions
Sintilimab
Pemetrexed
+2 more
Locations
1
China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Start Date
August 23, 2018
Primary Completion Date
February 13, 2023
Completion Date
February 13, 2023
Last Updated
February 27, 2023
NCT07143110
NCT06885697
NCT04577599
NCT06974604
NCT07035587
NCT04631770
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions